Cantor Fitzgerald Maintains Overweight on Harmony Biosciences, Raises Price Target to $58
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has maintained an Overweight rating on Harmony Biosciences and increased the price target from $51 to $58, indicating a positive outlook for the company's stock.
October 30, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Harmony Biosciences and increased the price target from $51 to $58, suggesting a positive outlook for the stock.
The increase in price target from $51 to $58 by Cantor Fitzgerald, along with maintaining an Overweight rating, indicates a strong positive sentiment from the analyst. This is likely to lead to a short-term increase in stock price as investors react to the upgraded target and positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100